Article
A diverse landscape of FGFR alterations and co-mutations suggests potential therapeutic strategies in pediatric low-grade gliomas.
Nature communications - 31 Jul 2025
Apfelbaum April A, Morin Eric, Sturm Dominik, Ayoub Georges, DiGiacomo Jeromy, Bahadur Sher, Chandarana Bhavyaa, Power Phoebe C, Cusick Margaret M, Novikov Dana, Prabhakar Prem, Jones Robert E, Vogelzang Jayne, Bossi Connor C, Malinowski Seth, Woodward Lewis M, Jones Tania A, Jeang John, Lamson Sarah W, Collins Jared, Cai Kelly Y, Jones Jacquelyn S, Oh Sehee, Jeon Hyesung, Wang Jinhua, Cameron Amy, Rechter Patrick, De Leon Angela, Murugesan Karthikeyan, Montesion Meagan, Albacker Lee A, Ramkissoon Shakti H, van Tilburg Cornelis M, Hardin Emily C, Sievers Philipp, Sahm Felix, Yeo Kee Kiat, Rosenberg Tom, Chi Susan N, Wright Karen D, Hébert Steven, Peck Sydney, Picca Alberto, Larouche Valérie, Renzi Samuele, Buhrlage Sara J, Bale Tejus A, Smith Amy A, Touat Mehdi, Jabado Nada, Fischer Eric S, Eck Michael J, Baird Lissa, Witt Olaf, Kleinman Claudia L, Nguyen Quang-De, Sheer Denise, Alexandrescu Sanda, Jones David T W, Ligon Keith L, Bandopadhayay Pratiti
Abstract excerpt
Oncogenic alterations in fibroblast growth factor receptor (FGFR)-family proteins occur across cancers, including pediatric gliomas. Our genomic analysis of 11,635 gliomas across ages finds that 5.3% of all gliomas harbor FGFR alterations, with an incidence of almost 9% in pediatric gliomas. Alterations in FGFR proteins are differentially enriched by age, tumor grade, and histology, with FGFR1 alterations...
Read the complete abstract on PubMed